As Pfizer kills failed PhIII programs for Bavencio, where do they go from here in R&D?
Pfizer managed to disappoint just about everyone this morning with its full-year outlook as generic competition eats into their big franchise revenue streams. For a company that has long prided itself on the numbers, it was a telling setback that follows a wide-ranging reorganization plan that is culling staff and eliminating segments of R&D.
Shares were down close to 3% Tuesday morning, ahead of the opening bell.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.